Pharmacokinetics of metformin after intravenous and oral administration to man. 1979

P J Pentikäinen, and P J Neuvonen, and A Penttilä

The kinetics of 14C-metformin have been studied in five healthy subjects after oral and intravenous administration. The intravenous dose was distributed to a small central compartment of 9.9 +/- 1.61 (X +/- SE), from which its elimination could be described using three-compartment open model. The elimination half-life from plasma was 1.7 +/- 0.1 h. Urinary excretion data revealed a quantitatively minor terminal elimination phase with a half-life of 8.9 +/- 0.7 h. After the intravenous dose, metformin was completely excreted unchanged in urine with a renal clearance of 454 +/- 47 ml/min. Metformin was not bound to plasma proteins. The concentration of metformin in saliva was considerably lower than in plasma and declined more slowly. The bioavailability of metformin tablets averaged 50--60%. The rate of absorption was slower than that of elimination, which resulted in a plasma concentration profile of "flip-flop" type for oral metformin.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P J Pentikäinen, and P J Neuvonen, and A Penttilä
May 1999, The Journal of antimicrobial chemotherapy,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
March 1983, British journal of clinical pharmacology,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
May 1986, Acta pharmacologica et toxicologica,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
September 1979, British journal of clinical pharmacology,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
March 1989, British journal of clinical pharmacology,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
January 1984, Postgraduate medical journal,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
August 1980, Journal of pharmacokinetics and biopharmaceutics,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
April 1984, Journal of pharmacokinetics and biopharmaceutics,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
December 2011, Fitoterapia,
P J Pentikäinen, and P J Neuvonen, and A Penttilä
November 1997, American journal of veterinary research,
Copied contents to your clipboard!